March 26-28, 2019

Boston, USA

Day One
WEDNESDAY, MARCH 27, 2019

Day Two
THURSDAY, MARCH 28, 2019

08.00
Registration & Networking Breakfast

08.50
Chair’s Opening Remarks

Addressing Knowledge Gap in Immune Tolerance Induction by Connecting the Dots Between Transplantation, Allergies & Autoimmune Diseases

09.00
Antigen-Specific T Cell Profiles as Therapeutic Targets in Allergy and Autoimmune Disease

Synopsis

  • High-dimensional phenotyping identifies distinct antigen-specific T cell profiles using peripheral blood from patients with allergy and autoimmune diseas
  • Deletion, deviation, anergy, and exhaustion are potential tolerogenic outcomes of therapy
  • Tracking antigen-specific T cells during therapy may be a surrogate for clinical response

09.30
Antigen-Specific Immunotherapy for Treatment of Autoimmune Diseases

  • David Wraith Institute Director of Immunology & Immunotherapy and Professor of Immunology , University of Birmingham

Synopsis

  • A review of different approaches for induction of antigen-specific immunotherapy
  • A report on recent clinical trials of the approach for immunotherapy of autoimmune diseases and
  • A discussion on the potential for combination approaches to promote antigenspecific immunotherapy

10.00
Antigen Specific Approaches to Food Allergy & Immunogenicity

  • Michael Boyne VP of Product Development & Analytics , Cour Pharmaceuticals

Synopsis

  • Inducing tolerance without immune suppression by harnessing nanoparticle technology
  • Proof of principle data for Peanut Allergy
  • Proof of principle data for Recombinant Proteins

10.30
Speed Networking & Morning Refreshments

11.30
Protection from Childhood Allergies & Inflammatory Bowel Disease

  • Erika von Mutius Professor of Pediatric Allergology , Dr. von Hauner Children’s Hospital

Synopsis

  • Prevention of allergic and autoimmune diseases in environment rich microbial exposure
  • Potential mechanisms of preventive approach
  • Translational aspects and considerations

12.00
Anti-Drug Antibody Responses: Past, Present & Future

  • Jack Ragheb Senior Medical Fellow for Immunology- Global Patient Safety , Eli Lilly

Synopsis

  • Review the history of ADA responses
  • Review the present state of ADA responses
  • Discuss the future state of ADA responses

12.30
Antigen-Specific Tolerance for Transplantation

  • Xunrong Luo Director-Translational Research , Duke Transplant Center, Duke University

Synopsis

  • A top-down approach can be used to overcome the complexity of alloantigens for transplantation tolerance
  • Multiple parallel mechanisms involving both innate and adaptive immune cells are implicated for transplantation tolerance
  • B cells play a critical role in tolerance resistance in pre-sensitized hosts

13.00
Networking Lunch

Identification & Validation of Novel Targets & Mechanism of Actions for Antigen-Specific Immune Tolerance Induction Antoon Van

14.00
Targeting Dendritic Cells to Restore Immune Tolerance in Auto- Immune- & Allergic Diseases

Synopsis

  • Tolerogenic dendritic cells (DCs) can induce distinct types of regulatory T-cells (Tregs)
  • Induction of tolerogenic DCs that drive increased antigen-specific Tregs may restore immune tolerance in autoimmune and allergic diseases

14.30
Antigen-Specific Tolerance Induction in Rheumatoid Arthritis

  • Ranjeny Thomas Professor of Rheumatology at University of Queensland; Director , Dendright

Synopsis

  • What are the opportunities and challenges of antigen-specific tolerance induction in a systemic inflammatory autoimmune disease?
  • How does the autoimmune induction phase differ from the inflammatory effector phase in rheumatoid arthritis and what are the implications for therapeutic tolerising strategies?
  • What type of immunomonitoring could contribute to evaluation of the outcome of tolerising strategies in rheumatoid arthritis?

15.00
Target Identification in Immune-Mediated Disorders Including Autoimmune Diseases, Allergies, Anti-Drug Responses & Tumor Immunology

  • Roland Martin Head- Department of Neuroimmunology & Multiple Sclerosis Research Neurology Clinic , University Hospital Zurich, University Zurich

Synopsis

• Unbiased and systematic identification of target antigens for T cells using combinatorial chemistry and bioinformatics
• Identification of disease-relevant T cells in autoimmune diseases
• How does the autoimmune T cell response relate to recognition of foreign antigens as triggers?

15.30
Afternoon Refreshments & Poster Session

Advancing Pre-Clinical Development of Novel Antigen-Specific Immune Tolerance Therapies

16.00
TOL2: An Antigen Specific Tolerogenic Therapy for the Treatment of Myasthenia Gravis

Synopsis

  • TOL2 treatment modalities
  • Tolerance induction and maintenance using TOL2
  • Preclinical development of TOL2

16.30
Engineering Red Blood Cells for Immune Tolerance Using Cell Squeeze® Technology

  • Finola Moore Associate Director of Immune Tolerance , SQZ Biotechnologies

Synopsis

  • The SQZ process efficiently delivers antigen into red blood cells (RBCs) and primes cells for rapid clearance in the liver and spleen
  • SQZ’d RBCs reduce CD4+ and CD8+ T cell responses against model antigens and human autoantigens
  • SQZ’d RBCs delay or prevent onset of T1D in adoptive transfer model

17.00
Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?

Synopsis

  • What does it take to achieve a robust proof-of-concept for antigen-specific immune tolerance induction strategies in complex auto-immune mediated diseases?
  • Delivering on the hype and investment thus far – how to translate promising science and clear opportunity into safe and effective antigen-specific tolerance inducing therapeutics?
  • The most promising route to funding: how to secure funding, through cross-industry collaborations, to fuel early clinical trial studies and beyond?

17.30
Chair’s Closing Remarks & End of Day One